BetterLife Enters Research Agreement with Medical College Wisconsin for TD-0148A Neurological Receptor Studies
September 09, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company...
BetterLife-Carleton University Research Team Secure Mitacs Accelerate Funding to Study the Therapeutic Effect of TD-010 in Chronic Anxiety
July 22, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on...
BetterLife to Present at the Emerging Growth Conference
July 19, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, July 19, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA:NPAU ), an emerging biotechnology company...
BetterLife Provides H1 2021 Progress Update
July 12, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company...
UPDATE -- Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer
July 07, 2021 11:45 ET
|
Reset Pharmaceuticals, Inc.
Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...
Reset Pharmaceuticals Enters into Exclusive Worldwide License Agreement with NYU Langone Health for Intellectual Property and Data on Psilocybin and Related Psychedelics for the Treatment of Mental Illness in Patients with Life-Threatening Diseases, Including Cancer
July 07, 2021 07:00 ET
|
Reset Pharmaceuticals, Inc.
Transaction accelerates Reset Pharmaceuticals’ lead psilocybin program, targeting severe demoralization, as well as anxiety, and depression, in cancer patients Stephen Ross, MD, a leading expert in...
BetterLife Announces Exercise of Over-Allotment Option in Public Offering
June 25, 2021 09:51 ET
|
BetterLife Pharma Inc.
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, June 25, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the...
BetterLife Secures Mitacs Funding in Collaboration with Carleton University Research Team for TD-0148A Preclinical Depression Studies
June 24, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 24, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on...
BetterLife Pharma Engages Global Financial and Corporate Communications Agency
June 22, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 22, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company, is pleased...
BetterLife Pharma to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17th
June 15, 2021 08:00 ET
|
BetterLife Pharma Inc.
VANCOUVER, British Columbia, June 15, 2021 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA:NPAU), an emerging biotech company focused on...